CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer

CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer

Although radiation therapy has recently made great advances in cancer treatment, the majority of patients diagnosed with pancreatic cancer (PC) cannot achieve satisfactory outcomes due to intrinsic and acquired radioresistance. Identifying the molecular mechanisms that impair the efficacy of radioth...

Full description

Bibliographic Details
Main Authors: Bin Lan, Siyuan Zeng, Shuman Zhang, Xiaofan Ren, Yuming Xing, Isabella Kutschick, Susanne Pfeffer, Benjamin Frey, Nathalie Britzen-Laurent, Robert Grützmann, Nils Cordes, Christian Pilarsky
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
pancreatic cancer
CRISPR-Cas9
radiotherapy
radioresistance
DYRK1A
Harmine
Online Access:https://www.mdpi.com/2072-6694/14/2/326

Internet

https://www.mdpi.com/2072-6694/14/2/326

Similar Items